Medical device company CartiHeal secured a $2.5 million investment from Bioventus, bringing the latest financing round to $21 million. The funding will go to CartiHeal's ongoing Agili-C IDE clinical study.
Here are three things to know:
1. CartiHeal developed the proprietary Agili-C implant for the treatment of joint surface lesions in traumatic and osteoarthritic joints.
2. The Agili-C implant IDE multinational pivotal study is set to include 250 patients. The trial aims to demonstrate the superiority of the implant over the surgical standard of care, microfracture and debridement, to treat cartilage or osteochondral defects in osteoarthritic knees and knees without degenerative damages.
3. CartiHeal's latest financing round was led by aMoon. Johnson & Johnson Innovation, Peregrine Ventures, Elron and Bioventus contributed.
More articles on biologics:
Osteo-P bone graft substitute receives 510(k) clearance: 6 things to know
Watch out for spinal biologics in 2018 — 2 key thoughts from Dr. Roger Hartl